Results 21 to 30 of about 79,696 (205)

Activity of Cyclic AMP Phosphodiesterases and Adenylyl Cyclase in Peripheral Nerve after Crush and Permanent Transection Injuries [PDF]

, 1998
Recent studies demonstrate that cAMP levels are tightly controlled during demyelination and remyelination in Schwann cells as cAMP decreases to 8–10% of normal following both sciatic nerve crush or permanent transection injury and only begins to increase
Poduslo, Joseph F., Walikonis, Randall S.   +1 more
core   +1 more source

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review

Journal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso, João Crispim Ribeiro, Eduardo P. Miranda   +2 more
doaj   +1 more source

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model [PDF]

, 2016
Purpose Phosphodiesterase type-5 inhibitor (PDE5i) tadalafil administration in men with erectile dysfunction is associated with increased testosterone/estradiol ratio, leading to hypothesize a potential increased effect of androgen action on target ...
Aversa, Antonio, Bimonte, V. M., Fittipaldi, Simona, Francomano, Davide, Greco, E. A., Lenzi, Andrea, Migliaccio, S., Papa, V., Wannenes, F.   +8 more
core   +1 more source

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

Journal of Research in Pharmacy Practice, 2015
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are ...
Nahid Eskandari, Omid Mirmosayyeb, Gazaleh Bordbari, Reza Bastan, Zahra Yousefi, Alireza Andalib   +5 more
doaj   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

Pulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson, Oisin Butler, Roger Hesselstrand, Katsiaryna Holl, Kjell Jansson, Rogier Klok, Göran Rådegran, Stefan Söderberg, Barbro Kjellström   +8 more
doaj   +1 more source

TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan [PDF]

, 2014
BACKGROUND AND OBJECTIVE Small cell lung cancer (SCLC) is one of the most challenging tumors to treat due to high proliferation rate, early metastatic dissemination and rapid development of chemotherapy resistance.
El-Khamisy, Sherif F, Meisenberg, Cornelia, Schmid, Peter, Ward, Simon E   +3 more
core   +3 more sources

cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. [PDF]

, 2015
Blocking Plasmodium falciparum transmission to mosquitoes has been designated a strategic objective in the global agenda of malaria elimination. Transmission is ensured by gametocyte-infected erythrocytes (GIE) that sequester in the bone marrow and at ...
A Dawn, A Heiber, A Merckx, A Pantaleo, A Sudo, AE Bianco, Audrey Lorthiois, Bernina Naissant, C Lavazec, C Lavazec, C Syin, Catherine Lavazec, CJ Taylor, D Yokoyama, DA Baker, David A. Baker, DK Muhia, Dominique Soldati-Favre, Donatella Taramelli, E Farfour, E Lasonder, E Ling, Eloise Thompson, F Hawking, F Silvestrini, F Silvestrini, Florence Breil, Florian Dupuy, G Deplaine, Ghania Ramdani, Gordon Langsley, HM Taylor, I Koshino, J Bain, K Leykauf, Kenneth Vernick, KM Tang, L Chen, L McRobert, L Wentzinger, LK Read, M Aingaran, M Boolell, M Hliscs, M Tiburcio, M Tiburcio, ME Smalley, MJ Lopez-Barragan, MK Dearnley, MW Dixon, N Goto, N Mohandas, Odile Mercereau-Puijalon, QL Fivelman, R Aguilar, R Joice, RE Sinden, RE Sinden, RL Coppel, Ross Cummings, RW Moon, S D'Alessandro, S Kunz, S Sanyal, SM Knebel, SP Davies, SP Kim, T Bousema, T Harrison, T Ono, T Seebeck, W Trager, WB Smith 2nd, Yoann Duffier, Yolanda Corbett   +74 more
core   +9 more sources

Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. [PDF]

Biochem Pharmacol, 2020
Zuccarello E, Acquarone E, Calcagno E, Argyrousi EK, Deng SX, Landry DW, Arancio O, Fiorito J.   +7 more
europepmc   +2 more sources

Phenanthrenes from as Novel Phosphodiesterase-5 Inhibitors

Natural Product Communications, 2017
Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon ...
Prapapan Temkitthawon, Kanokwan Changwichit, Nantaka Khorana, Jarupa Viyoch, Khanit Suwanborirux, Kornkanok Ingkaninan   +5 more
doaj   +1 more source

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source